FOR IMMEDIATE RELEASE
This statement can be attributed to Denise-Hyater Lindenmuth (MA, MBA), Executive Director of the National Women's Health Network. Contact Director of Communications Adele Costa at [email protected] or by phone at 631 – 538 – 6348 for comments and questions.
The National Women’s Health Network (NWHN) is gravely concerned about the ruling that effectively reverses the FDA’s approval of mifepristone, which is one of the two commonly used prescription drugs for medication abortion and miscarriage management. This ruling bans the sale of mifepristone nationwide and creates a severe barrier to access for an estimated 40 million people. For more than 20 years, the NWHN has supported the safe use of mifepristone, and when taken in combination with misoprostol, it is effective for abortion care management. In fact, the FDA decided to permanently remove the medically unnecessary in-person dispensation requirement in December 2021 allowing clinicians to provide prescriptions by telemedicine and mail, a campaign the NWHN worked tirelessly on for over 10 years. We will continue to provide updates on this critical matter across our social media channels and on our website. We will also advocate in coalition with our partners to lift this ban, and will keep you appraised of opportunities to get involved. If you or someone you know is seeking abortion care, there are still legal options available. Consult Plan C, the Miscarriage and Abortion Hotline, or Aid Access for up-to-date information on access from medical experts.
The National Women’s Health Network is supported by our members. We fight for a world where we all have access to high-quality, affordable health care by shaping policy at the federal level, funding and training grassroots health organizations, and providing accurate, reliable health information to the public.